Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV002261669 | SCV002541782 | uncertain significance | not provided | 2021-09-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003095888 | SCV003505666 | uncertain significance | Catecholaminergic polymorphic ventricular tachycardia 1 | 2022-06-10 | criteria provided, single submitter | clinical testing | This variant is present in population databases (no rsID available, gnomAD 0.003%). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RYR2 protein function. This variant has not been reported in the literature in individuals affected with RYR2-related conditions. This sequence change replaces serine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 2276 of the RYR2 protein (p.Ser2276Ile). |